Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells

by Jonathan Metts, Heath L. Bradley, Zhengqi Wang, Neil P. Shah, Reuben Kapur, Jack L. Arbiser, Kevin D. Bunting
Published 2017-06-01

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy

by Alexander A Warkentin, Michael S Lopez, Elisabeth A Lasater, Kimberly Lin, Bai-Liang He, Anskar YH Leung, Catherine C Smith, Neil P Shah, Kevan M Shokat
Published 2014-12-01

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

by Ehab Atallah, Charles A. Schiffer, Kevin P. Weinfurt, Mei-Jie Zhang, Jerald P. Radich, Vivian G. Oehler, Javier Pinilla-Ibarz, Michael W. N. Deininger, Li Lin, Richard A. Larson, Michael J. Mauro, Joseph O. Moore, Ellen K. Ritchie, Neil P. Shah, Richard T. Silver, Martha Wadleigh, Jorge Cortes, James Thompson, Jessica Guhl, Mary M. Horowitz, Kathryn E. Flynn
Published 2018-04-01